EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials

Roukoz Abou-Karam, Min Seo Kim, So Mi Jemma Cho, Fouad Bitar, Shoshana Gady, Fangzhou Cheng, Abigail Grace Thompson, Elizabeth W Karlson, Pradeep Natarajan, Patrick T Ellinor, Borek Foldyna, Musie S Ghebremichael und 4 weitere

JACC · 2026-09 · 88 (10) · 1050-1067

DOI: 10.1016/j.jacc.2025.12.032 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2026-09. Verfasst von Roukoz Abou-Karam und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Cardiovas…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Genetic Risk Score. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Coronary artery disease (CAD) polygenic risk scores (PRS) may identify individuals at elevated genetic risk "flying under the radar" in contemporary practice. The aims of the PROACT (Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis) trials are to prospectively identify these individuals, quantify subclinical coronary plaque, and slow its progression with pharmacologic interventions. OBJECTIVES: The aim of this study is to report interim feasibility and implementation findings from PROACT, a genotype-first, biobank-enabled trial, characterizing eligibility yield, callback engagement, and subclinical coronary atherosclerosis on coronary computed tomographic angiography among individuals with high CAD PRS. METHODS: Within a hospital-based biobank, adults 40 to 75 years of age with high CAD PRS, without cardiovascular disease, and not on lipid-lowering therapy were invited. The authors characterize 2,495 eligible individuals with high CAD PRS, report on the feasibility and early operational outcomes of a genotype-first callback strategy for a clinical trial in the first 1,314 invited, and describe plaque prevalence by age and sex in the first 204 participants using coronary computed tomographic angiography. RESULTS: Among 64,092 genotyped participants, 2,495 (3.9%) were eligible and had high CAD PRS despite low clinical risk (median 10-year pooled cohort equations risk for atherosclerotic cardiovascular disease 3%; Q1-Q3: 1%-8%). Recruitment showed high engagement: among 1,314 invited individuals, 283 (21.5%) opted in, and 204 (15.5%) completed baseline imaging. Compared with participants who did not opt in, those who opted in had higher specialty care engagement and lived closer to the study site. Analysis of the first 204 participants enrolled by January 31, 2025 (mean age 56.3 ± 8.5 years, 69% women), showed that despite the low clinical risk and favorable cardiovascular health (mean Life's Essential 8 score 73.3 ± 11.5 vs the U.S. average of ∼65), one-half the participants (102 of 204) had subclinical plaque. Subclinical plaque prevalence was 76.2% in men and 38.3% in women and was high across age groups. CONCLUSIONS: These exploratory findings highlight the feasibility of implementing genotype-first recruitment for prevention trials and reveal a large proportion of "silent" high-genetic risk individuals with subclinical plaque for whom pharmacotherapy could be beneficial but who remain undetected by standard clinical assessments. (Polygenic Risk Based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health [PROACT 1], NCT05819814; Polygenic Risk Based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine [PROACT 2], NCT05850091).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseGenetic Risk ScoreAdultAgedFemaleHumansMaleMiddle AgedComputed Tomography AngiographyCoronary AngiographyFeasibility StudiesRisk Assessment

Stichwörter der Autor:innen

atherosclerosiscoronary artery diseasecoronary computed tomography angiographypolygenic risk scoreprimary prevention

Autor:innen und Institutionen

  • Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridg…
  • Mass General Brigham Personalized Medicine, Boston, Massachusetts, USA.
  • Cardiovascular Imaging Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA; MGH Biostatistics Center, Boston, Massachusetts, USA.
  • Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • NHGRI NIH HHS
  • National Heart Lung and Blood Institute

Zitieren

APA

Abou-Karam, R., Kim, M. S., Jemma Cho, S. M., Bitar, F., Gady, S., Cheng, F., Thompson, A. G., Karlson, E. W., Natarajan, P., Ellinor, P. T., Foldyna, B., Ghebremichael, M. S., Atlas, S. J., Ridker, P. M., Lu, M. T., & Fahed, A. C. (2026). Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials. JACC, 88(10), 1050-1067. https://doi.org/10.1016/j.jacc.2025.12.032

Vancouver

Abou-Karam R, Kim MS, Jemma Cho SM, Bitar F, Gady S, Cheng F, et al. Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials. JACC. 2026;88(10):1050-1067. doi:10.1016/j.jacc.2025.12.032

BibTeX
@article{AbouKaram2026,
  author = {Abou-Karam, Roukoz and Kim, Min Seo and Jemma Cho, So Mi and Bitar, Fouad and Gady, Shoshana and Cheng, Fangzhou and Thompson, Abigail Grace and Karlson, Elizabeth W and Natarajan, Pradeep and Ellinor, Patrick T and Foldyna, Borek and Ghebremichael, Musie S and Atlas, Steven J and Ridker, Paul M and Lu, Michael T and Fahed, Akl C},
  title = {Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials},
  journal = {JACC},
  year = {2026},
  volume = {88},
  number = {10},
  pages = {1050--1067},
  doi = {10.1016/j.jacc.2025.12.032}
}
Kostenlos starten →